Physician profile
Ali A Farooqui
NPI 1598076705
$392,530.22
in general payments reported to CMS, 2019-2025
28 companies · $206K in 2025
The $206K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $596 · 2020: $405 · 2021: $926 · 2022: $11K · 2023: $82K · 2024: $92K · 2025: $206K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $300K · Travel and Lodging: $33K · Honoraria: $33K · Food and Beverage: $13K · Education: $46.28.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $300,115.00 |
| Travel and Lodging | $33,037.63 |
| Honoraria | $32,982.50 |
| Food and Beverage | $13,203.31 |
| Education | $46.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $284,693.06 | 2021-2025 | |
| Braeburn INC. | $39,820.36 | 2024-2025 | Brixadi |
| Vanda Pharmaceuticals INC. | $37,904.32 | 2025 | Fanapt |
| Bioxcel Therapeutics, INC. | $20,246.68 | 2023-2024 | Igalmi |
| Brainsway USA INC | $2,207.51 | 2022 | |
| Alkermes, INC. | $1,054.90 | 2019-2025 | Lybalvi, Aristada |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $718.07 | 2020-2025 | Caplyta |
| Neuronetics, INC. | $660.81 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $624.12 | 2022-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $555.49 | 2019-2025 | Rexulti, Nuedexta |
| Janssen Pharmaceuticals, INC | $511.88 | 2019-2025 | Spravato, Invega Sustenna |
| Abbott Laboratories | $429.43 | 2021-2023 | Jeti |
| Idorsia Pharmaceuticals US INC | $410.03 | 2022-2023 | Quviviq |
| Axsome Therapeutics, INC. | $394.81 | 2022-2024 | Auvelity, Sunosi |
| Neurocrine Biosciences, INC. | $361.86 | 2022-2023 | Ingrezza |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $311.33 | 2024-2025 | Cobenfy |
| Sage Therapeutics, LLC | $218.25 | 2022-2023 | |
| Tris Pharma INC | $199.51 | 2023-2024 | Dyanavel Xr, Quillichew Er, Quillivant |
| Davol INC. | $196.32 | 2024 | Phasix Mesh |
| Allergan, INC. | $179.93 | 2020 | |
| Livanova USA, INC. | $168.16 | 2024 | Vns Therapy Symmetry Model 8103 Generator |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $129.14 | 2019-2023 | |
| Biogen, INC. | $122.54 | 2024 | Zurzuvae |
| Novo Nordisk INC | $118.25 | 2024 | Wegovy |
| Acadia Pharmaceuticals INC | $114.23 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $85.00 | 2024 | |
| Pfizer INC. | $79.32 | 2021 | |
| Bausch Health US, LLC | $14.91 | 2023 | Aplenzin, Wellbutrin |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ali Farooqui listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.